GlaxoSmithKline
GSK
$36.63
Share price
0.16%
Change (1 day)
4.18%
Change (1 year)
Categories
P/S ratio for GlaxoSmithKline (GSK)
P/S ratio as of December 2023 (TTM): 2.06
According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.06266. At the end of 2023 the company had a P/S ratio of 2.06.
P/S ratio history for GlaxoSmithKline from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.06 | 11.62% |
| 2022 | 1.85 | -21.36% |
| 2021 | 2.35 | 11.79% |
| 2020 | 2.10 | -22.19% |
| 2019 | 2.70 | 17.15% |
| 2018 | 2.31 | 3.51% |
| 2017 | 2.23 | -12.8% |
| 2016 | 2.55 | -6.69% |
| 2015 | 2.74 | -1.16% |
| 2014 | 2.77 | -10.25% |
| 2013 | 3.09 | 23.35% |
| 2012 | 2.50 | -5.99% |
| 2011 | 2.66 | 13.69% |
| 2010 | 2.34 | -4.53% |
| 2009 | 2.45 | 10.57% |
| 2008 | 2.22 | -27.13% |
| 2007 | 3.04 | -13.47% |
| 2006 | 3.52 | -7.68% |
| 2005 | 3.81 | 1.99% |
| 2004 | 3.73 | -1.39% |
| 2003 | 3.79 | -10.04% |
| 2002 | 4.21 | -28.97% |
| 2001 | 5.93 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.89 | 88.53% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.41 | 16.95% | 🇺🇸 USA |
 Sanofi SNY | 2.40 | 16.37% | 🇫🇷 France |
 Merck MRK | 4.49 | 117.60% | 🇺🇸 USA |
 AstraZeneca AZN | 4.48 | 117.17% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 0.7362 | -64.31% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | 4.98 | 141.52% | 🇺🇸 USA |